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Available online xxxxBackground: Tissue-type plasminogen activator (TPA) and plasminogen activator inhibitor-1 (PAI-1) have been
shown to be associated with increased risk for stroke, however, the association with incident atrial ﬁbrillation
(AF) is unknown.
Methods:We examined 8265 individuals included in the PREVEND study. In all subjects, PAI-1 and TPA plasma/
serum levels weremeasured using an ELISA kit. Bymeans of univariate andmultivariate analyses the association
with incident AF was assessed.
Results: Mean age was age 49 ± 13 years, and 50% were women. Of the 8265 patients free of AF at baseline,
267 (3.2%) patients developed incident AF during a mean follow-up of 9.7 ± 2.4 years. Baseline median levels
of PAI-1 and TPA were 72.4 ng/ml and 3.1 ng/ml, respectively. In univariate analyses PAI-1 (Hazard ratio [HR]
1.10 95% Conﬁdence interval [CI] 1.04–1.16, p b 0.001) and TPA (HR 1.05, 95% CI 1.01–1.08, p = 0.014) were
associated with incident AF. However, after multivariate adjustment for age, sex, antihypertensive drugs, stroke,
heart failure, myocardial infarction, diabetes mellitus, peripheral arterial disease, smoking, NT-proBNP, alcohol
consumption, body mass index no signiﬁcant association was found.
Conclusion: In this community-based cohort, PAI-1 and TPA levels were not associated with incident AF.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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TPA
Atrial ﬁbrillation1. Introduction
Atrialﬁbrillation (AF) is a common cardiac arrhythmia and is amajor
public health problem [1,2]. It has a lifetime risk of one in four for per-
sons over the age of 55 years in the Netherlands [1,2]. AF itself is associ-
ated with a substantial risk of stroke or thrombo-embolism [3]. The
otherway around, recent experimental data suggest that hypercoagula-
bility has the potential to cause or promote AF [4]. Tissue-type plasmin-
ogen activator (TPA) is synthesized by endothelial cells and activates
the proﬁbrinolytic proenzyme plasminogen. Plasminogen activator
inhibitor-1 (PAI-1) inhibits the activity of TPA and thereby the ﬁbrino-
lytic process. Both are markers of ﬁbrinolysis and are risk factors for
thrombosis and atherosclerosis [5,6]. In several patient categories it is
shown that an increased level of TPA or PAI-1 is associated withy, Thoraxcenter, University of
ox 30.001, 9700 RB Groningen,
. This is an open access article under
Plasminogen activator inhibit
/doi.org/10.1016/j.ijcard.2018cardiovascular outcome and mortality. For instance healthy individuals
who have high levels of antigen TPA have a higher risk of future stroke
[7]. Cross-sectional studies in patients with prevalent AF reported ele-
vated levels of TPA or PAI-1 in these patients [8,9]. Furthermore, in pa-
tients with prevalent AF, increased levels of TPA have been associated
with an increased risk of major adverse events (e.g. transitory ischemic
attack, stroke, myocardial infarction) and all-cause mortality [10].
It is, however, unknown whether increased levels of PAI-1 or TPA in
the general population, who did not have AF at baseline, are associated
with an increased risk for incident AF. Therefore we investigated in a
contemporary cohort of individuals without AF whether increased
levels of PAI-1 or TPA are associated with an increased risk for incident
AF during follow-up.
2. Methods
2.1. Population
ThePREVENDwas founded in1997 and includes a cohort of 8592 individuals [11]. The
inclusion and validation of patients who developed AF have been described before [2,11].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 2
Univariate and multivariate analyses.
Variable Hazard ratio (95% CI) p-Value
Univariate
PAI-1 (per 50 ng/ml) 1.10 (1.04–1.16) b0.001
TPA (per 5 ng/ml) 1.05 (1.01–1.08) 0.014
TPA:PAI-1 ratio (per 0.1 units) 0.88 (0.73–1.07) 0.212
Multivariate
PAI-1 (per 50 ng/ml) 1.03 (0.94–1.13) 0.548
TPA (per 5 ng/ml) 1.03 (0.97–1.10) 0.296
TPA:PAI-1 ratio (per 0.1 units) 0.97 (0.81–1.17) 0.742
PAI-1 = plasminogen activator inhibitor, TPA = tissue plasminogen activator. Multivari-
ate analysis adjusted for: age, sex, antihypertensive drugs, stroke, heart failure,myocardial
infarction, diabetes mellitus, peripheral arterial disease, smoking, NT-proBNP, alcohol
consumption, body mass index.
2 B.A. Mulder et al. / International Journal of Cardiology xxx (2018) xxx–xxxBrieﬂy, 7786 individuals with a urinary albumin excretion N 10mg/L and 3395 individuals
with a urinary albumin excretion b 10mg/Lwere invited to the PREVENDoutpatient clinic.
The ﬁnal cohort consisted of 8592 individuals. At the baseline visit, in addition to detailed
information about demographics, health behaviors, anthropometric measurements,
cardiovascular, andmetabolic risk factors, also blood samples and two 24-h urine samples
on 2 consecutive days were collected. For present analysis, individuals without any stan-
dard 12-lead ECG (n = 248) were excluded, and those with prevalent AF (n = 79). For
the ﬁnal analysis 8265 individuals were included. The measuring of PAI-1 and TPA has
been described before [12]. In brief, in PREVEND blood was drawn and anticoagulated
with EDTA and stored at−80 °C. Plasma antigen levels of PAI-1 and t-PA were measured
using an ELISA kit from Technoclone GmbH (Vienna, Austria) [12]. The PREVEND study
was approved by the institutionalmedical Ethics Committee and conducted in accordance
with the Declaration of Helsinki. All individuals provided written informed consent.
2.2. Follow-up
The follow-up duration was calculated as the time between the baseline visit to the
last contact date, death, or 31 December 2008, whichever came ﬁrst.
2.3. Incident atrial ﬁbrillation and covariates
Incident AF ascertainment and covariate deﬁnitions have been previously described
[2,13]. Brieﬂy, incident AF was diagnosed if either atrial ﬂutter or AF was present on a
12-lead ECG obtained at one of the three PREVEND follow-up visits or at an outpatient
visit or hospital admission in the two hospitals in the city of Groningen.
2.4. Statistical analysis
A statistical weightingmethodwas used in the prespeciﬁed Cox proportional-hazards
regression analyses, to adjust the overselection of individuals with microalbuminuria at
baseline, and allow generalization of results to the general population [13]. Individual
characteristics were presented as mean ± standard deviation or median (range) for
continuous variables and counts with percentages for categorical variables. We ﬁrst per-
formed an univariate analysis with PAI and TPA as continuous variables and subsequently
a multivariate analysis which adjusted for age, sex, antihypertensivemedication, previous
stroke, prevalent heart failure, previous myocardial infarction, diabetes mellitus, periph-
eral arterial disease, smoking, NT-proBNP, alcohol use N2 units/week, and body mass
index (as previously described [2]). Theproportionality assumptionwas checkedby calcu-
lating the Schoenfeld residuals, and where needed time-varying covariates were included
to avoid proportionality violations. All analyses were performed using R package (version
3.03), and a p value b 0.05 was considered as statistically signiﬁcant.
3. Results
The present population contained 8265 individuals with a mean age
of 49 ± 13 years, half of them were women (50.2%). Individual charac-
teristics are shown in Table 1. In total, 267 (3.2%) of 8265 individuals
developed incident AF during 9.7 ± 2.4 years of follow-up. BaselineTable 1
Population characteristics.
Characteristic Total population
(n = 8265)
Inc
(n
Age (years) - mean ± SD 49 ± 13 62
Male sex - no. (%) 4120 (49.8) 18
Body mass index (kg/m2) - mean ± SD 26.1 ± 4.2 27
Systolic blood pressure (mmHg) - mean ± SD 129 ± 20 14
Diabetes - no. (%) 310 (3.8) 24
Previous myocardial infarction - no. (%) 251 (3.1) 41
Prevalent heart failure - no. (%) 18 (0.2) 6 (
Previous stroke - no. (%) 81 (1.0) 9 (
Peripheral artery disease - no. (%) 291 (3.7) 28
Antihypertensive medication - no. (%) 1098 (16.1) 10
Oral antidiabetic medication - no. (%) 115 (1.7) 11
Statin - no. (%) 333 (4.9) 32
Total cholesterol (mmol/L) - median (range) 5.6 (4.9–6.3) 5.8
Glucose (mmol/L) - median (range) 4.7 (4.3–5.1) 5.0
NT-proBNP (ng/L) - median (range) 37.3 (16.6–72.6) 10
Creatinin (umol/L) - median (range) 82.0 (74.0–92.0) 88
eGFR (ml/kg/min) median (range) 80 (71–90) 75
Cystatin C (mg/L) - median (range) 0.8 (0.8–0.9) 0.9
High sensitive CRP (mg/L) - median (range) 1.3 (0.6–2.9) 2.0
PAI-1 (ng/ml) - median (range) 72.4 (41.7–124.8) 98
TPA (ng/ml) - median (range) 3.1 (2.3–4.7) 3.7
TPA:PAI-1 ratio (range) 0.048 (0.027–0.081) 0.0
AF = atrial ﬁbrillation, NT-proBNP = N-terminal Pro-brain natriuretic peptide, PAI-1 = plasm
Please cite this article as: B.A. Mulder, et al., Plasminogen activator inhibit
PREVEND study, Int J Cardiol (2018), https://doi.org/10.1016/j.ijcard.2018median levels of PAI-1 and TPA were 72.4 ng/ml and 3.1 ng/ml, re-
spectively. In univariate analyses, PAI-1 (Hazard ratio [HR] 1.10 95%
Conﬁdence interval [CI] 1.04–1.16, p b 0.001) and TPA (HR 1.05, 95%
CI 1.01–1.08, p = 0.014) were associated with incident AF. However,
after multivariate adjustment for age, sex, antihypertensive drugs,
stroke, heart failure, myocardial infarction, diabetesmellitus, peripheral
arterial disease, smoking, NT-proBNP, alcohol use N 2 units/week, and
body mass index, no signiﬁcant association was found (Table 2).
3.1. Sensitivity analysis
In addition to PAI-1 and TPA the TPA:PAI-1 ratio was analyzed
which was not associated with incident AF (Table 2). Also additional
gender speciﬁc analysis generated no signiﬁcant p-values: interaction
p-values for male versus females, for TPA, PAI-1 and TPA:PAI-1 ratio
were 0.87, 0.48, and 0.37 respectively. The same holds for age which
had no inﬂuence on the association of incident AF.
4. Discussion
The present analysis showed that increased levels of PAI-1 and TPA
were not associated with an increased risk of incident AF, after multi-
variable adjustment, in a large contemporary, community-based cohort
free of AF at baseline. Earlier reports showed that PAI-1 and TPA were
associated with thromboembolic outcomes in patients with knownident AF
= 267)
No AF
(n = 7998)
p-Value
(incident AF versus no AF)
± 9 49 ± 13 b0.001
7 (70.0) 3933 (49.2) b0.001
.9 ± 4.2 26.0 ± 4.2 b0.001
3 ± 23 129 ± 20 b0.001
(9.3) 286 (3.6) b0.001
(16.1) 210 (2.7) b0.001
2.2) 12 (0.2) b0.001
3.4) 72 (0.9) 0.001
(11.2) 263 (3.4) b0.001
0 (43.9) 998 (15.2) b0.001
(4.8) 104 (1.6) 0.002
(14.0) 301 (4.6) b0.001
(5.2–6.6) 5.5 (4.9–6.3) b0.001
(4.6–5.6) 4.7 (4.3–5.1) b0.001
3.4 (44.4–249.5) 36.0 (16.2–70.0) b0.001
.0 (78.0–98.0) 82.0 (73.0–92.0) b0.001
(68–84) 80(72–90) b0.001
(0.8–1.0) 0.8 (0.7–0.9) b0.001
(0.8–3.6) 1.3 (0.6–2.9) b0.001
.7 (55.8–160.8) 71.9 (41.2–123.3) b0.001
(2.6–5.5) 3.1 (2.3–4.6) b0.001
50 (0.029–0.078) 0.048 (0.027–0.081) 0.635
inogen activator inhibitor, TPA = tissue plasminogen activator.
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3B.A. Mulder et al. / International Journal of Cardiology xxx (2018) xxx–xxxcardiovascular disease [7]. Only limited data is available concentrating
on ﬁbrinolytic function in patients who have AF. The ﬁbrinolytic system
and its relation to AF and its associated underlying mechanisms are
complex and not completely understood [14]. Earlier reports in patients
with lone AF suggested that AF itself modiﬁed ﬁbrinolytic markers [15].
Also PAI-1 levels were found predictive of a successful cardioversion,
and considered as an independent predictor for AF after coronary artery
bypass surgery [16,17].
What did the increased levels of PAI-1 andTPAmean in patientswho
developed AF in the present population. It may mirror early conse-
quences of endothelial damage or dysfunction or a form of systemic
inﬂammation,which can lead to AF in the years thereafter [18]. Another
potential explanation is that it might be due to inﬂammation, endothe-
lial damage, and ﬁbrinolysis or due to confounders (hypertension or in-
sulin resistance) or a combination [14]. Intriguing as inﬂammation plays
an important role in the development of AF and inﬂammation may rise
from many associated conditions (i.e. obesity, hypertension, coronary
artery disease) [19]. Additionally it could be related to structural remod-
eling of the atria, by means of ﬁbrosis, and even could induce electrical
remodeling of the atria, which could eventually lead to AF. Why was
PAI-1 and TPAnotmultivariable associatedwith future AF in thepresent
study? As the multivariate analyses indicated it is likely due to cardio-
vascular risk factors and diseases which are associated with the
increased levels and could therefore be considered as potential con-
founder. For example, hypertension, heart failure, or ischemic heart
disease can all lead to endothelial damage or inﬂammation [6,18]. Also
the PREVEND population is rather young with a mean age of 49 years.
As experimental studies have shown that hypercoagulability promotes
the development of a substrate for AF and AF progression [4]. Additional
studies on the role of coagulation and ﬁbrosis and their role in atrial re-
modeling and development of AF are evidently needed [20].
4.1. Strengths and limitations
Strengths of our study are the large and contemporary community-
based cohort, with a detailed clinical assessment and a strong validation
of incident AF and cardiovascular events. Most limitations are the
result of the observational design of the community-based cohort
study. Probably not all asymptomatic paroxysmal AF episodes are cap-
tured as we did not have continuous ECG recordings. Furthermore, the
number of individuals with incident AF was modest, which reduced
our statistical power to detect signiﬁcant associations between PAI-1
or TPA and incident AF.
5. Conclusions
In this large contemporary cohort PAI-1 and TPA levels were not
associated with the onset of AF.
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